HRP20170918T1 - Soli piperazina kao d3/d2 antagonista - Google Patents
Soli piperazina kao d3/d2 antagonistaInfo
- Publication number
- HRP20170918T1 HRP20170918T1 HRP20170918TT HRP20170918T HRP20170918T1 HR P20170918 T1 HRP20170918 T1 HR P20170918T1 HR P20170918T T HRP20170918T T HR P20170918TT HR P20170918 T HRP20170918 T HR P20170918T HR P20170918 T1 HRP20170918 T1 HR P20170918T1
- Authority
- HR
- Croatia
- Prior art keywords
- antagonists
- piperazine salts
- piperazine
- salts
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000004885 piperazines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0700339A HU230748B1 (hu) | 2007-05-11 | 2007-05-11 | Új piperazin só és előállítási eljárása |
| EP08750834.7A EP2155696B1 (en) | 2007-05-11 | 2008-05-13 | Piperazine salts as d3/d2 antagonists |
| PCT/HU2008/000044 WO2008139235A2 (en) | 2007-05-11 | 2008-05-13 | Novel piperazine salts as d3/d2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170918T1 true HRP20170918T1 (hr) | 2017-09-22 |
Family
ID=89987512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170918TT HRP20170918T1 (hr) | 2007-05-11 | 2017-06-16 | Soli piperazina kao d3/d2 antagonista |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US7943621B2 (hr) |
| EP (1) | EP2155696B1 (hr) |
| JP (1) | JP2010526861A (hr) |
| KR (2) | KR20100018493A (hr) |
| CN (1) | CN101679315B (hr) |
| AP (1) | AP2009005012A0 (hr) |
| AU (1) | AU2008249772B2 (hr) |
| BR (1) | BRPI0811199A2 (hr) |
| CA (1) | CA2684404C (hr) |
| CO (1) | CO6241112A2 (hr) |
| CY (1) | CY1119076T1 (hr) |
| DK (1) | DK2155696T3 (hr) |
| EA (1) | EA017270B1 (hr) |
| EC (1) | ECSP099772A (hr) |
| ES (1) | ES2628025T3 (hr) |
| GE (1) | GEP20125522B (hr) |
| HK (1) | HK1140473A1 (hr) |
| HR (1) | HRP20170918T1 (hr) |
| HU (2) | HU230748B1 (hr) |
| IL (1) | IL201533A0 (hr) |
| LT (1) | LT2155696T (hr) |
| MA (1) | MA31434B1 (hr) |
| MX (1) | MX2009012182A (hr) |
| MY (1) | MY148078A (hr) |
| NI (1) | NI200900203A (hr) |
| NZ (1) | NZ580642A (hr) |
| PL (1) | PL2155696T3 (hr) |
| PT (1) | PT2155696T (hr) |
| RS (1) | RS56036B1 (hr) |
| SI (1) | SI2155696T1 (hr) |
| TN (1) | TN2009000458A1 (hr) |
| TW (1) | TWI424846B (hr) |
| UA (1) | UA102225C2 (hr) |
| WO (1) | WO2008139235A2 (hr) |
| ZA (1) | ZA200907511B (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010526832A (ja) * | 2007-05-11 | 2010-08-05 | リヒター ゲデオン エヌワイアールティー． | カルバモイル−シクロヘキサン誘導体の溶媒和物および結晶形態 |
| HUP0700353A2 (en) * | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| HUP0700369A2 (en) | 2007-05-24 | 2009-04-28 | Richter Gedeon Nyrt | Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia |
| EA018064B1 (ru) * | 2007-08-03 | 2013-05-30 | Рихтер Гедеон Нирт. | Способ лечения депрессии |
| US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| EA023972B1 (ru) * | 2008-02-21 | 2016-08-31 | Рихтер Гедеон Нирт. | Стабильный твёрдый препарат карипразина для перорального введения и способ его получения |
| SI2317852T1 (sl) | 2008-07-16 | 2015-04-30 | Richter Gedeon Nyrt. | Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja |
| HU230067B1 (hu) * | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Új piperazin só és eljárás előállítására |
| HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
| HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
| US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
| HU231227B1 (hu) | 2012-11-29 | 2022-03-28 | Richter Gedeon Nyrt. | Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére |
| CN105218484B (zh) * | 2015-09-14 | 2018-02-23 | 安徽省逸欣铭医药科技有限公司 | 酒石酸卡利拉嗪及其制备方法和医药用途 |
| CN106543105B (zh) * | 2015-09-22 | 2019-10-11 | 江苏恩华药业股份有限公司 | 一种盐酸卡利拉嗪晶型ⅳ及其制备方法 |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| WO2018229794A1 (en) | 2017-06-13 | 2018-12-20 | Cipla Limited | Amorphous form of cariprazine |
| WO2019016828A1 (en) * | 2017-07-15 | 2019-01-24 | Msn Laboratories Private Limited, R&D Center | NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE |
| CN111712486B (zh) * | 2018-09-21 | 2024-09-13 | 上海诚妙医药科技有限公司 | 卡利拉嗪盐酸盐的晶型及其制备方法及其用途 |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| JP7537811B2 (ja) | 2020-08-26 | 2024-08-21 | 上海雲晟研新生物科技有限公司 | カリプラジン医薬組成物、製造方法及び応用 |
| US20230149392A1 (en) * | 2021-10-28 | 2023-05-18 | Abbvie Inc. | Treatment of major depressive disorder |
| CN116675654A (zh) | 2022-02-22 | 2023-09-01 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途 |
| WO2024072930A1 (en) * | 2022-09-30 | 2024-04-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| HU227534B1 (en) * | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
-
2007
- 2007-05-11 HU HU0700339A patent/HU230748B1/hu not_active IP Right Cessation
-
2008
- 2008-05-09 US US12/118,437 patent/US7943621B2/en active Active
- 2008-05-13 AU AU2008249772A patent/AU2008249772B2/en active Active
- 2008-05-13 WO PCT/HU2008/000044 patent/WO2008139235A2/en active Application Filing
- 2008-05-13 CN CN2008800156277A patent/CN101679315B/zh active Active
- 2008-05-13 PT PT87508347T patent/PT2155696T/pt unknown
- 2008-05-13 BR BRPI0811199-5A2A patent/BRPI0811199A2/pt not_active Application Discontinuation
- 2008-05-13 CA CA2684404A patent/CA2684404C/en not_active Expired - Fee Related
- 2008-05-13 ES ES08750834.7T patent/ES2628025T3/es active Active
- 2008-05-13 AP AP2009005012A patent/AP2009005012A0/xx unknown
- 2008-05-13 DK DK08750834.7T patent/DK2155696T3/en active
- 2008-05-13 UA UAA200912891A patent/UA102225C2/ru unknown
- 2008-05-13 KR KR1020097022188A patent/KR20100018493A/ko active Application Filing
- 2008-05-13 GE GEAP200811599A patent/GEP20125522B/en unknown
- 2008-05-13 EA EA200971046A patent/EA017270B1/ru unknown
- 2008-05-13 NZ NZ580642A patent/NZ580642A/en unknown
- 2008-05-13 HU HUE08750834A patent/HUE034796T2/en unknown
- 2008-05-13 KR KR1020157019598A patent/KR101668973B1/ko active IP Right Grant
- 2008-05-13 LT LTEP08750834.7T patent/LT2155696T/lt unknown
- 2008-05-13 MY MYPI20094708A patent/MY148078A/en unknown
- 2008-05-13 PL PL08750834T patent/PL2155696T3/pl unknown
- 2008-05-13 EP EP08750834.7A patent/EP2155696B1/en active Active
- 2008-05-13 SI SI200831816T patent/SI2155696T1/sl unknown
- 2008-05-13 RS RS20170549A patent/RS56036B1/sr unknown
- 2008-05-13 MX MX2009012182A patent/MX2009012182A/es active IP Right Grant
- 2008-05-13 JP JP2010507992A patent/JP2010526861A/ja not_active Withdrawn
- 2008-07-08 TW TW097125707A patent/TWI424846B/zh active
-
2009
- 2009-10-15 IL IL201533A patent/IL201533A0/en active IP Right Grant
- 2009-10-26 ZA ZA200907511A patent/ZA200907511B/xx unknown
- 2009-10-30 TN TNP2009000458A patent/TN2009000458A1/fr unknown
- 2009-11-09 NI NI200900203A patent/NI200900203A/es unknown
- 2009-11-30 EC EC2009009772A patent/ECSP099772A/es unknown
- 2009-12-07 CO CO09139912A patent/CO6241112A2/es not_active Application Discontinuation
- 2009-12-07 MA MA32405A patent/MA31434B1/fr unknown
-
2010
- 2010-07-08 HK HK10106638.3A patent/HK1140473A1/xx unknown
-
2017
- 2017-05-12 CY CY20171100512T patent/CY1119076T1/el unknown
- 2017-06-16 HR HRP20170918TT patent/HRP20170918T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170918T1 (hr) | Soli piperazina kao d3/d2 antagonista | |
| ZA201000413B (en) | Piperazine compounds with herbicidal action | |
| GB0908772D0 (en) | New salts 756 | |
| HK1145677A1 (en) | Substituted piperidino dihydrothienopyrimidines | |
| GB0720038D0 (en) | New compounds | |
| GB0720041D0 (en) | New Compounds | |
| IL201165A0 (en) | CRIg ANTAGONISTS | |
| IL202666A0 (en) | Substituted piperazines | |
| IL199913A0 (en) | Salts 668 | |
| GB0704000D0 (en) | Salts 670 | |
| ZA201000395B (en) | Substituted piperazines as cb1 antagonists | |
| ZA201003909B (en) | Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide | |
| GB0722769D0 (en) | New compounds | |
| GB0701273D0 (en) | New compounds | |
| GB0702459D0 (en) | Salts 669 | |
| GB0900404D0 (en) | New compounds 4 | |
| HU0700395D0 (en) | New compounds | |
| EP2261210A4 (en) | SUBSTITUTED SULFONYLPIPERAZINE DERIVATIVE IN POSITION 3 | |
| IL202339A0 (en) | Azacyclylbenzamide derivatives as histamine-3 antagonists | |
| GB0721013D0 (en) | New Salts | |
| EP2184272A4 (en) | PIPERAZINE DERIVATIVE | |
| GB0912946D0 (en) | New compounds 5 | |
| GB2480936B (en) | Paper tool construction | |
| GB0714728D0 (en) | Salts | |
| GB0813850D0 (en) | Salts |